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Abstract 
Objective To describe how clinicians use decision aids. 
Background A 98-patient factorial-design randomized trial of the Statin 
Choice decision vs. standard educational pamphlet; each participant 
had a 1:4 chance of receiving the decision aid during the encounter 
with the clinician resulting in 22 eligible encounters. 
Design Two researchers working independently and in duplicate re-
viewed and coded the 22 encounter videos. 
Setting and participants Twenty-two patients with diabetes (57% of 
them on statins) and six endocrinologists working in a referral di-
abetes clinic randomly assigned to use the decision aid during the 
consultation. 
Main outcome measures Proportion and nature of unintended use of 
the Statin Choice decision aid. 
Results We found eight encounters involving six clinicians who did not 
use the decision aid as intended either by not using it at all (n = 5; 
one clinician did use the decision aid in three encounters), offering 
inaccurate quantitative and probabilistic information about the risks 
and benefits of statins (n = 2), or using the decision aid to advance 
the agenda that all patients with diabetes should take statin (n = 1). 
Clinicians used the decision aid as intended in all other encounters. 
Conclusions Unintended decision aid use in the context of videotaped en-
counters in a practical randomized trial was common. These instances 
offer insights to researchers seeking to design and implement effec-
tive decision aids for use during the clinical visit, particularly when 
clinicians may prefer to proceed in ways that the decision aid appar-
ently contradicts. 
Keywords: decision aid, diabetes, randomized trial, shared decision mak-
ing, video analyses 
Decision aids are tools that can help clinicians share evidence-based 
information about treatment options with patients in order to increase 
the likelihood that patients will be informed about research evidence 
and help them participate in the decision-making process [1]. We de-
sign decision aids for use during the clinical visit, making it a design 
criterion that the decision aid should start a conversation about the 
issue between patients and clinicians (i.e. physicians, nurse practi-
tioners) [2]. An exchange of information and views can set the stage 
for chronic disease decisions that respect both the best available re-
search evidence and the values and preferences of the informed pa-
tient, thereby facilitating shared treatment decision making [3]. 
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How clinicians use decision aids in practice during the clinical visit 
has received little research attention. In part because of limited adop-
tion of decision aids in practice, the available literature focuses on cli-
nicians’ perceptions rather than direct observations of actual use dur-
ing the clinical encounter [4–6]. For example, based on systematic 
reviews of 31 publications covering 28 studies – mostly qualitative – 
from the UK, USA, Canada and Netherlands among others, Gravel and 
colleagues studied health professionals’ perceptions of barriers and fa-
cilitators to using decision aids [4]. The barriers most often reported 
were time constraints (18/28), lack of applicability because of patient 
characteristics (12/28), and lack of applicability because of the clini-
cal situation (12/28). The most cited facilitators were: provider mo-
tivation (15/28), positive impact on the clinical process (11/28) and 
positive impact on patient outcomes (10/28). 
Despite the contributions of such studies to the understanding of 
clinicians’ attitudes towards using decision aids, they do not account 
for the ways in which clinicians actually use and misuse decision aids 
in the clinical encounter.Amore naturalistic study of clinicians’ use of 
decision aids during the office visit should help answer this important 
question in translating the science of decision support into practice. 
Methods 
The Statin Choice trial 
The present study of clinicians’ use of the Statin Choice decision aid 
during the visit is part of a larger cross-sectional observational qual-
itative design nested within a 98-patient randomized trial of this de-
cision aid vs. a standard educational pamphlet [7]. 
Another publication describes in detail the development of the de-
cision aid [2]. In brief, the decision aid Statin Choice is a single-page 
document informing patients of the risks and benefits of statins (cho-
lesterol-lowering medications that reduce cardiovascular risk). This 
decision aid, designed for use during the visit, relies on a graphical 
representation of risk (100 ordered faces indicating both the likelihood 
of having and not having an adverse event) to indicate a tailored es-
timate of the 10-year coronary heart disease risk for patients like the 
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participant who take or do not take statins (the latest version of this 
decision aid can be downloaded from our website, http://kerunit.e-
bm.org). Of importance, clinicians who participated in the trial pro-
vided input into the design and content of the decision aid. 
The Statin Choice trial execution and main results have appeared 
elsewhere [7]. Briefly, this trial, approved by the Mayo Institutional 
Review Board, used a 2 ¥ 2 factorial randomized trial design result-
ing in one of four visits (i.e. 22 visits) in which clinicians and patients 
used the Statin Choice decision aid during the consultation. Partici-
pating patients had type 2 diabetes and were able (had no major cog-
nitive, sensorial or language barriers) and willing to provide written 
informed consent; 57% were already on statins (we enrolled patients 
already taking statins so that clinicians could use the decision aid to 
review the decision to use statins and to evaluate whether the inter-
vention could enhance drug adherence in those who opted to con-
tinue; participating providers and patients were blind to this hypoth-
esis). Participating clinicians, who also gave written informed consent 
to participate in the trial, were endocrinologists (faculty and train-
ees) delivering care in their usual setting: a referral clinic in a tertiary 
care centre for patients with diabetes and other metabolic concerns. 
In this context, clinicians introduced the decision aid to patients 
as part of a study to help patients with diabetes and their clinicians 
make choices about cholesterol medication. During most visits the cli-
nician’s focus seemed not on ameliorating cardiovascular risk (the fo-
cus of the Statin Choice decision aid), but on improving glycemic con-
trol. These medical encounters were structured along history taking, 
review of laboratory tests, a physical examination and discussions of 
lifestyle issues, including diet and exercise, blood sugar control and 
self-management education. The discussion about use of statins oc-
cupied no more than 5 of the 40–50 minute consultation visit usually 
at the beginning or at the end of the visit. 
Participating clinicians randomly allocated to using the Statin Choice 
during the consultation received 2–5 minutes of training that con-
sisted in one of the investigators using the decision aid with the cli-
nician as if the clinician was the patient. After the clinician’s first use 
of the decision aid, the investigators, who had watched this visit on a 
remote video monitor, would offer suggestions to the clinician when-
ever they observed important deviations from the intended use of the 
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decision aid. The encounters reported here include these and every 
subsequent visit. 
The trial results supported the notion that the decision aid furthered 
the conversation, reduced uncertainty around the decision and im-
proved short-term adherence to statins [7]. 
Video recording 
Video recording of the visits took place through an unobtrusive 
camera mounted on the ceiling of each of the consultation offices. 
This angle provided direct view of the patient, the clinician and the 
space between them, often a desk surface with a computer monitor. 
The decision aid was printed in a large A3-sized paper that occupied 
that space. Patients and clinicians could turn off the video or the au-
dio or both from a wall panel that also indicated the camera status, 
although this feature was never used. The audio in each of the videos 
was isolated and transcribed directly. 
Video analyses 
To analyse the 22 video recordings and the direct transcripts of 
their audio (of the 23 eligible encounters, one was not video recorded 
because of equipment malfunction), we employed a qualitative tech-
nique, conversational analysis, to assess patient– clinician communi-
cation during the medical encounter [8,9]. One of us (R.A), devised 
the analytic approach by (1) reviewing the literature on shared deci-
sion making in chronic disease [3] and about the development of the 
Statin Choice decision aid [2]; (2) generating criteria for the proper 
use of decision aids; and (3) checking these criteria with the authors 
of the decision aid (A.J.W., V.M.M). Based on these criteria, R.A. and 
A.J.W. coded transcripts to determine how clinicians used the Statin 
Choice decision aid during the trial. 
Coding scheme 
The intended or expected use of the decision aid required the clini-
cian to use the decision aid to disclose to patients the risks and ben-
efits of taking or not taking statins in quantitative terms. While the 
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wording in the decision aid invited the patient to take part in the deci-
sion-making process, the decision aid did not require a particular ex-
tent of patient participation in deliberation or decision making, allow-
ing for patients and clinicians to arrive at a model of decision making 
in usual ways. The intended use of the decision aid allowed for sty-
listic deviations (e.g. trivial changes in wording) as long as this idio-
syncratic use did not contradict the information in or purpose of the 
decision aid. 
We judged that clinicians had not used the decision aid as intended 
when (1) it was not used at all; (2) when clinicians used the deci-
sion aid merely to convey that there was no choice for the patient 
but to be on statins based on current recommendations [10,11]; or 
(3) when clinicians communicated grossly inaccurate data or omit-
ted critical information about risks or benefits (coding guide avail-
able upon request). 
Working independently, two researchers separately coded each vid-
eos and audio transcripts (the video provided non-verbal context to 
the utterances in the transcript and clarified silences). These research-
ers were an anthropologist who generated the coding scheme, had not 
participated in the design or conduct of the trial, and was not famil-
iar with the care of people with diabetes (R.A.), and a nurse practi-
tioner caring routinely for patients with diabetes who participated in 
the design and use of the decision aid and who participated in the de-
sign and conduct of the trial (A.J.W.). We compare the chance-inde-
pendent inter-rater reliability of these researchers using the Phi statis-
tic [12]. In case of disagreements, the two coders compared notes and 
discussed the best code for the encounter until they reached agree-
ment, using the rules used to reach that agreement in future codes. 
All eligible recorded interactions were of sufficient quality to allow 
transcription and codification. 
Results 
Use of the decision aid as intended 
The between-reviewer simple agreement for classifying the use 
of the decision aid as intended or not intended was 82%; chance- 
independent agreement was acceptable (Phi = 0.73). In the 22 
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encounters that included the decision aid, the six participating clini-
cians used the decision aid as intended in all but eight instances. For 
the majority of patients who had already decided to take statins prior 
to their consultation, the information the clinician conveyed with the 
assistance of the decision aid confirmed their choice as all decided to 
continue to use statins. The perceived benefits – however marginal 
for those at low risk (<10%) for coronary events at 10 years – and 
manageable or absent side effects appeared to contribute to shape 
these decisions. 
Box 1 offers an example of an interaction between a clinician and a 
middle-aged man recently diagnosed with diabetes. This example il-
lustrates the intended yet not ideal use of the decision aid and its ef-
fect on patient’s decision making. While the reviewers classified this 
encounter as one in which the clinician used the decision as intended, 
the clinician introduced some comments that indicated his own pref-
erence for the patient to use statins (e.g. by pointing to the patient’s 
elevated LDL-cholesterol levels) and left the patient to deliberate on 
this information. This illustrates the intended role of the decision aid: 
to create an informed patient enabled to participate to the extent de-
sired in making the decision. 
Unintended uses 
Five of the six clinicians did not use the decision aid as intended at 
least once: one clinician did not use the decision aid in any of his three 
encounters (which focused almost entirely on glycemic control); two 
other clinicians did not use the decision aid in one encounter each. 
One clinician used the decision aid to advance his agenda that all pa-
tients with diabetes should take statins. Two clinicians offered mis-
leading presentations of the probabilistic information about risks and 
benefits of statins. Except for the clinician who never used the decision 
aid, all unintended uses occurred after the first use of the decision aid. 
In the cases where the decision aid was not used at all, either car-
diovascular risk reduction through cholesterol control was not ad-
dressed, the clinician disclosed risk/benefit information to the pa-
tient without the decision aid, or the patient was already on statins. 
When the decision aid was used to advance a specific therapeu-
tic agenda, the clinician presented the decision aid to illustrate his 
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belief that all diabetic patients should take statins. The script in 
Box 2 is particularly telling of the conflict between the clinicians’ 
agenda of aggressive treatment and the role of choice implicit in us-
ing a decision aid: the clinician refers to the investigators as ‘they’ 
and suggests ‘they’ made a mistake in making him use the decision 
aid in this patient, who already knows more about the issues. In this 
Box 1 Intended use of the decision aid 
Dr: [Your cholesterol] should be half of what it is now. Let’s go over this 
together 
 [The clinician then introduces the decision aid; the patient puts his glasses on]. 
Dr: What is your risk of having a heat attack in the next 10 years? This table 
shows that you have an estimated 15–30% chance of having a heart at-
tack in the next 10years. 
 [Pointing to the first chart that describes patient’s risk of not taking statins for 
this risk group] 
Dr: Out of 100 people like you, about 20 will have a heart attack in the next 
10 years, and about 80 will not. 
 [Pointing to the second chart that describes the patient’s risk if he decides to 
take statins] 
Dr: From 80 to 85 [patients that avoided a heat attack], from 20 to 15 [pa-
tients that had a heart attack], that’s a significant risk reduction in rela-
tive terms, not absolute. 
Dr: ‘Statins do not cure cholesterol; it is like your diabetes problem. You need to 
take them every day.’ 
 [Patient asks the clinician for his opinion. The clinician then mentions that 
outside this study he recommends statins because it reduces cardiovascu-
lar risk but notes that it does not eliminate risk. Referring to the chart he 
notes]; Dr: They are not all greens [referring to the colour of the ‘happy 
faces’ used to denote the number of patients who would not have a heart 
attack in 10 years]. 
Dr: Based on the information, what do you want to do? Even with the best 
diet and exercise we expect 15% reduction in cholesterol levels, but 
your level is 160; it is too high. It needs to go well below that. This is en-
tirely up to you; you are the person that is going to take the medication. 
I am not here to tell you what to do. My job is to give you the best evi-
dence that we have. The decision is all yours, alone. And this is true for 
all conditions. This is how I, [Institution] envision my role. I don’t want to 
put words into your mouth. What do you want to do? 
Patient: The side effects are minimal [The patient decides that he wants to talk 
further with his primary physician before making a decision about start-
ing statin use.  
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instance, the clinician paid little attention to the uncertainty inher-
ent in population-based risk information. Instead, he combined a 
certain belief in the value of statin therapy with the quantitative 
risk information in the decision aid to impress upon the patient the 
need for aggressive control of all risk factors in all patients. Other 
videos also show clinicians making preference statements in favour 
of statin use, but without fundamentally affecting the decision aid 
Box 2 Unintended use – agenda-driven misuse 
Dr: It looks like your cholesterol and stuff is controlled rather well. One of the 
things they have us down here for, they want me to do this portion of 
it which is this business of why are you taking a statin. Did you have the 
information? Patient: I don’t have any information. 
Dr: You can look at that [the Statin Choice decision aid]. This explains why, at 
least from their perspective in doing this particular study to try and 
help patients be educated and why to treat with a statin which is Zocor 
. . . you also take Tricor, but that is mostly for triglycerides and Zocor is 
mostly for cholesterol. Your numbers read rather good. You are at 142, 
79, triglycerides, which is absolutely excellent. Forty-six is the HDL cho-
lesterol and the LDL is 80. Goals for diabetes, now, are about 70 or less. 
But they have circled your risk factors in regards to your risk of having 
heart disease. But you already know heart disease is something you 
may experience. This is the difference if you use the statin, how many 
people would have a heart attack and how many people would not. 
These are the people, because of the statin, who would be avoiding a 
heart attack. The higher the risk, the better the improvements. I abso-
lutely believe everyone with diabetes belongs on a statin. I think 
your [primary care] doctor is doing the right thing. Is there a differ-
ence between 80 and 70? Nobody knows. I think where you are, I would 
be quite content with that. That is excellent. That is helping your arter-
ies out. So does blood sugar control. The same thing with blood pres-
sure, keeping that in control also protects your heart. Studies that have 
been done and studies we are currently doing show when you control 
all those three main factors aggressively, the risk, the number of peo-
ple having a heart attack keep dropping. When you control all three, 
it cuts it at least 50% or more. So it is pretty impressive. That is, again, 
your eyes, and nerves and all of the other reasons with that control. . . . 
Questions? Patient: No, not any more. 
Dr: I think you don’t need a whole bunch of this to convince you of that, 
you already have some complications that convince you without too 
much doubt that you need to take care of the diabetes. 
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presentation. In contrast, one clinician misused the decision aid by 
fundamentally changing the presentation in the decision aid and 
introducing conflicting and contradictory risk/benefit information 
about statin use to the patient (Box 3 describes that encounter). 
Box 3 Unintended use – inaccurate information 
The clinician introduces the use of the decision aid and discusses the cardiovas-
cular risk factors and medications the patient is taking to reduce his car-
diovascular risk.] 
Dr: What does this mean? If you take 100 people like you, probably about 10, 
roughly, would have a heart attack in the next 10 years and 90 would 
not. Another way to look at this is to take 100 diabetics in a room; the 
90 in green are never going to have a heart attack in the next 10 years. 
You are in this group down here where 10 might [get a heart attack]. 
[The clinician informs a patient in the decision aid’s lowest risk category (less 
than 15% risk of myocardial infarction in the next 10 years) that he is 
among the 10 people out of 100 like the patient who will have a heart at-
tack in the next 10 years. This use directly contradicts the information on 
the decision aid that conveys risk/ benefit information in a probabilis-
tic and impersonal way. For example, the decision aid text reiterates that 
the information refers to ‘our guess of what will happen to 100 people like 
you’. Here is your risk if you decide not to take statins. About 10 will have 
a heart attack in the next 10 years, and about 90 will not.] 
[The text on the aid itself notes that patients should ‘keep in mind that we do 
not know what will happen to you’. The clinician however ignores it and 
continues with the description]: 
Dr: So the question is, is it worth starting this medication in order to reduce 
your risk out of the 10 there. If we started on statins in your case, there 
would be two out of the 10 that would end up not having a heart at-
tack. It would reduce that risk. For eight, it wouldn’t change that out-
come. So for the two that would be taking would be helpful, but for 
eight there wouldn’t be any difference. 
[Again, here the clinician departs significantly from the text of the Statin Choice 
decision aid by focusing on the 10 of 100 people expected to have a heart 
attack rather than on the 100 people one would need to treat with statins 
as indicated in the aid.] 
[The clinician continues to use decision aid as intended, including asking the 
patient what he wants to do about statins. The patient decided to consult 
with his primary care physician before making a decision about starting 
statins]. 
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Discussion 
Principal findings 
In this study, clinicians used the decision aid as intended, that is, 
to provide information about the risks and benefits of taking and not 
taking statins, in 64% of the interventions. After a short introduction 
to the decision aid, only in two cases did clinicians offer incorrect in-
formation about risks and benefits of statin use to patients. These 
findings demonstrate that, when designed properly, basic training 
is largely sufficient for the proper use of the decision aid during the 
clinical encounter. 
Despite using the decision aid as intended in the majority of the 
clinical encounters, the decision aid was severely misused in eight 
encounters. Five out of six clinicians used the decision aid at least 
once in an unintended way and one avoided its use altogether with 
his patients despite investigators’ reassurances that the goal of the 
decision aid was to facilitate the communication of risk/benefit in-
formation to patients, and that use would not interfere with clini-
cian style, judgment or medical authority. The clinician we quoted as 
providing an example of the intended use of the decision aid (Box 1) 
is also responsible for one unintended use (he suggested that every 
patient should be on statins, using the decision aid to merely illus-
trate this point). Thus, individual clinicians varied in their use of the 
decision aid, even during a video-monitored randomized trial. This 
suggests that failures to use decision aids appropriately do not arise 
from fundamental opposition to decision aids, per se, but rather may 
arise from variability in the perceived relevance of decision aids to 
the care of different patients. 
In addition to situations in which clinicians and patients engaged 
in shared deliberation, we identified situations in which clinicians, 
after using the decision aid, recommended a course of action with-
out any patient input. In other cases, clinicians forced patients to de-
liberate on the information presented and make decisions alone. In 
still other instances, clinicians felt the need to add further meaning 
to the quantitative presentation in the decision aid and, in doing so, 
often framed the presentation in a way that could be construed as fa-
vouring statin use. 
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An alternative view is that these clinician ad libs represent subtle 
ways in which clinicians appropriated or resisted the use of the deci-
sion aid during the clinical encounter. In other words, clinicians may 
have perceived the decision aid as undermining their professional au-
tonomy or challenging their clinician’s role during the clinical encoun-
ter. Thus, further research could help determine the extent to which 
clinicians framing utterances are more likely to take place when cli-
nicians perceive that the decision aid would lead the patient to adopt 
a course of action contrary to the clinicians’ own preferences and 
recommendations. 
Also, clinicians could have been responding to external pressures 
such as guidelines and quality-of-care standards when they misused 
the decision aid or uttered framing statements. Dominant clinical 
guidelines recommend and quality of care performance parameters 
require that most if not all patients with diabetes take statins aim-
ing to achieve certain LDL-cholesterol goals [13]. These recommenda-
tions assume all patients with diabetes are at high coronary risk and 
that the lower the LDL cholesterol level the better the outcomes, and 
therefore they must take statins. While the available evidence only 
weakly supports these assumptions [14], these guidelines were often 
mentioned during the encounters we studied. Guideline and quality-
of-care pressures, alongside marketing to clinicians and direct-to-con-
sumer advertising provide a challenging environment in which to ex-
ercise informed choice and shared decision making [15]. 
Study limitations and strengths 
This study has some limitations and strengths. We drew inferences 
from observing video recorded encounters, without access to the pa-
tient or clinicians’ account of what happened during the visit. Fur-
thermore, while the trial provided a unique point of entrée into clini-
cian’s use of the decision aid and shared decision making, it does not 
substitute for the observation of clinicians’ use of such tools during 
their regular clinical encounters, when feasible. Whether our findings 
are applicable to other settings (e.g. continuity care, primary care) or 
decisions is unclear. 
On the other hand, analysis of the video recordings and audio tran-
scripts in this setting provides interesting hypotheses-generating 
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insights that do not come from stated barriers in practitioner sur-
veys, but rather from directly observed behaviours. While this study 
does not investigate the ways clinicians would use the Statin Choice 
decision aid in their regular clinical encounters, it provides a quasi-
natural experiment to explore the way clinicians actually used it. The 
unique opportunity to observe and analyse the actual use of decision 
aids in a clinical trial, employing two very different, highly qualified 
investigators (with different degrees of familiarity with clinical visits) 
using a common coding scheme with reasonable coding agreement, 
speaks to the strength of this study. 
Furthermore, our findings appear consistent with the available lit-
erature on barriers (concerns about fit between the decision aid and 
the specific patient and clinical circumstances, for instance) to the 
use of decision aids [4–6]. In contrast to concerns about time con-
straints, our study demonstrated that providers could efficiently use 
a decision aid mostly as intended. It is not possible to identify partic-
ular motivators for use (beyond participation in the clinical trial); in 
many cases the decision aid was introduced to the patient as part of 
a research study, as opposed to being framed as part of routine or de-
sirable clinical care. 
Conclusion 
In conclusion, while most participating clinicians were able to use 
the tool as intended with minimal training, unintended use of decision 
aids occurred commonly. This is particularly striking in the context of 
a randomized trial in which the clinicians agreed to participate and 
in which they knew they were video recorded. The gross unintended 
use and the subtler clinician utterances framing the information pre-
sented provide novel insights into the nature of clinical decision mak-
ing in practice and represent areas of necessary future implementation 
research. Decision aids designed for use during the clinical visit need 
to take these insights into account for their successful implementa-
tion. When properly designed and implemented, these tools can help 
clinicians and their patients share information and enable patients to 
participate, to the extent they desire, in making treatment decisions. 
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